1. Introduction {#s0005}
===============

The kidney is made up of a heterogeneous population of cells which function together to perform a number of tightly controlled, complex and interdependent processes. It is frequently targeted by pathogenic immune responses against renal autoantigens or by local manifestation of systemic autoimmunity. In fact, many studies have revealed that kidney disease is associated with inflammation[@bib1].

High mobility group box 1 (HMGB1) is a nuclear DNA-binding protein discovered over 30 years ago[@bib2]. Under normal circumstances, it participates in a variety of biological processes including transcription, DNA repair, differentiation and development[@bib3]. However, when released from necrotic or activated cells it functions as a potent proinflammatory cytokine which exerts its actions through multiple cell-surface receptors including the receptor for advanced glycation end products (RAGE) and toll-like receptors (TLRs), TLR2, TLR4 or TLR9. Recently, studies have shown that HMGB1 plays an important role in the pathogenesis of a variety of kidney diseases.

This review focuses on the role of HMGB1 in the pathogenesis of different kidney diseases including acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy (DN), antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), clear cell renal cell carcinoma (ccRCC) and both granulomatous and lupus nephritis (GN and LN respectively). It also attempts to evaluate the potential for modulating the HMGB1-mediated signaling pathway in the treatment of kidney diseases.

2. Characteristics of HMGB1 {#s0010}
===========================

HMGB1 is a member of the high mobility group nuclear protein family and one of the most evolutionarily conserved proteins[@bib4]. The human *HMGB1* gene is located on chromosome 13q12 and six polymorphic loci throughout the gene locus have recently been identified. HMGB1 is almost always present in the nuclei of mammalian cells and is released into the extracellular medium in response to appropriate stimuli, a process in which the inflammasome plays an important role. The release occurs both by active secretion and a passive process subsequent to inflammation factor stimulation of inflammatory cells such as dendritic cells and monocyte/macrophages. After transport from the nucleus to the cytoplasm, HMGB1 moves into the secretory lysosome and is secreted from the cell through exocytosis[@bib5]. When released from necrotic or burst cells, the damage signal is passed to adjacent cells[@bib6].

In the cytoplasm, HMGB1 regulates cellular processes such as autophagy and apoptosis[@bib7], [@bib8], [@bib9], [@bib10]. Autophagy is a process associated with the degradation of intracellular organelles following sequestration within double-membrane delimited vacuoles. HMGB1 is important for oxidative stress--mediated autophagy and serves as a new target for the treatment of stress-associated disorders[@bib8]. Through autophagy, HMGB1 contributes to cell proliferation[@bib11] but it also activates endonuclease G and DNA fragmenting factor (DFF) to promote apoptosis[@bib12]. In fact, recent research suggests that heat shock protein *β*1 (HSPB1) is a response to cardiomyocyte apoptosis to which HMGB1 contributes[@bib13].

HMGB1 released into the extracellular fluid serves as a damage-associated molecular pattern molecule (DAMP) to mediate the noninfectious inflammatory response[@bib14]. As shown in [Fig. 1](#f0005){ref-type="fig"}, extracellular HMGB1 can interact with other soluble molecules, cellular receptors and surface molecules such as RAGE, TLR2, TLR4, TLR9, syndecan-3, CD24-Siglec-10, macrophage antigen-1, chemokine (C-X-C motif) receptor 4 (CXCR4), certain integrins, and the T cell Ig domain and mucin domain proteins. It interacts with RAGE at its COOH-terminal motif to inhibit invasive migration and metastasis[@bib15]. It interacts with TLR2/4 receptors[@bib16] to promote the translocation of cytoplasmic NF-*κ*B into the nucleus and induce an inflammatory response. It binds to chemokine (C-X-C motif) ligand 12 (CXCL12) to form a HMGB1--CXCL12 heterocomplex which interacts with CXCR4 to promote the migration of monocytes and fibroblasts[@bib17]. Finally, HMGB1 stimulation contributes to tumor progression by causing overexpression of miR-21 depending on the interleukin-6 (IL-6)/Stat3 signaling axis[@bib18].

3. Expression of HMGB1 in renal diseases {#s0015}
========================================

As a potential inflammatory cytokine, HMGB1 plays multiple roles in the pathogenesis of renal disease. In recent years, numerous studies have reported the association between HMGB1 expression and renal disease[@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34]. Evidence from these studies reveals that in renal disease HMGB1 levels in blood and urine, the expression of HMGB1 in renal tissue, and the levels of HMGB1 in the cytoplasm and extracellular medium are all elevated. [Table 1](#t0005){ref-type="table"} lists studies implicating the expression of HMGB1 in various renal diseases.

4. HMGB1 and renal disease {#s0020}
==========================

4.1. HMGB1 and AKI {#s0025}
------------------

AKI is defined as an abrupt and sustained decrease in kidney function[@bib35]. It occurs frequently in patients with end-stage liver disease and cirrhosis and portends a poor prognosis. AKI can result from a number of causes including ischemia/reperfusion injury (IRI), sepsis, hemodynamic changes, inflammation and nephrotoxity[@bib36].

A cross-sectional study[@bib23] in patients with AKI showed an elevated serum HMGB1 level related to inflammatory parameters such as ferritin and orosomucoid. A study in TLR4 deficient (*TLR4*^−/−^) mice[@bib37] with IRI of the kidney not only indicated an increased expression of HMGB1 in the kidney but also found serum creatinine and tubular injury were reduced after treatment with anti-HMGB1 antibodies. The results show that HMGB1 promotes kidney injury through TLR4 suggesting inhibiting the release of HMGB1 could protect against AKI. In fact, Wu et al.[@bib38] showed that preconditioning wild-type mice with recombinant HMGB1 (rHMGB1) before ischemia protects the kidney from TLR4-dependent IRI and that Siglec-G upregulation is involved.

A study exploring the effect of mycophenolate mofetil (MMF) on IRI[@bib39] demonstrated that plasma creatinine levels and renal damage were reduced by MMF treatment. TLR4 expression and the plasma concentration of cytokines were also reduced. However, there was no change in the concentration of HMGB1 suggesting MMF reduces TLR4 expression directly to improve renal function. A recent study[@bib40] reported CO-releasing molecule-2 decreased the activity of nuclear histone acetyltransferase and consequently inhibited the acetylation and release of HMGB1 to exert a protective effect against potentially lethal IRI of the kidney. HMGB1 released due to IRI reduces the survival of tubular epithelial cells (TECs) and augments inflammation. Glycyrrhizic acid inhibits the interaction of HMGB1 with TECs and attenuates renal injury following IRI and transplantation[@bib41]. These findings demonstrate that HMGB1 plays an important role in IRI through the TLR4 pathway.

4.2. HMGB1 and CKD {#s0030}
------------------

It has been shown that CKD is associated with chronic inflammation[@bib42]. A clinical trial involving 110 patients with CKD revealed that serum HMGB1 was significantly elevated and correlated with glomerular filtration rate (GFR) as well as with markers of inflammation and malnutrition. These included high-sensitivity C-reactive-protein (hs-CRP), IL-6, tumor necrosis factor (TNF), serum-albumin, hemoglobin A (1c) (HbA (1c)) and hemoglobin[@bib25]. The correlation was particularly strong in patients with vasculitis including Henoch--Schönlein purpura nephritis, and IgA nephropathy (IgAN) with glomerular crescents[@bib43]. In another study in rats with adenine-induced CKD[@bib26], the HMGB1 concentration was significantly increased suggesting it may be a potentially useful biomarker for this condition. Leelahavanichkul et al.[@bib24], using a recently characterized 5/6 nephrectomy (5/6Nx) mouse model of progressive CKD, found that HMGB1 was released from apoptotic cells and that CKD-sepsis could be attenuated by anti-HMGB1. Nakamura et al.[@bib44] studied the relationship between the RAGE ligand and asymmetric dimethylarginine (ADMA) in 20 nondiabetic normotensive CKD patients and found that HMGB1 elevation raised the level of ADMA. This suggests the active involvement of the AGE/HMGB-1--RAGE--ADMA axis in CKD.

Renal fibrosis resulting from CKD is an important public health concern. Tubulointerstitial fibrosis is characterized by the loss of renal tubules, an increased myofibroblast population, and accumulation of extracellular matrix proteins (ECM)[@bib45]. In a model of immune-mediated epithelial--mesenchymal transition (EMT) established in human proximal TECs (PTECs), human rHMGB1 treatment induced alterations in epithelial morphology consistent with EMT[@bib32]. The effect of HMGB1 was mediated at least in part by RAGE products and through induction of transforming growth factor-*β*1 secretion from PTECs. TLR2 is upregulated in kidneys of patients with tubulointerstitial damage[@bib46] and levels of TLR2, its danger ligands Gp96 and biglycan, and HMGB1 are increased in mice with obstructive nephropathy. The results demonstrate that TLR2 can initiate renal inflammation during progressive renal injury and that the absence of TLR2 does not affect the development of tubulointerstitial fibrosis. It is possible that the inhibition of HMGB1 alone or of HMGB1 and TLR2 together is more effective than inhibition of TLR2 alone in renal fibrosis. Recently, Tian et al.[@bib33] found HMGB1 facilitates M1 macrophage polarization in the early stage of unilateral ureter obstruction. Thus inhibition of HMGB1 release may alter macrophage phenotype and protect kidney tissue from injury and fibrosis. In summary, HMGB1 plays an important role in the pathogenesis of renal fibrosis by activating RAGE/TLR2/TLR4.

4.3. HMGB1 and DN {#s0035}
-----------------

DN is mainly the result of inflammatory processes and metabolic alterations caused by hyperglycemia[@bib47]. Kim et al.[@bib34] first reported the association between HMGB1 and DN, showing that in both cytoplasmic and nuclear patterns of diabetic renal glomerular cells and TECs, HMGB1 is highly expressed in contrast to cells in normal rats where HMGB1 is expressed in the nuclei only. RAGE expression and NF-*κ*B activity were also elevated in diabetic rats where the binding of NF-*κ*B to the RAGE promoter was increased. These findings suggest that HMGB1 released during hyperglycemia may induce renal injury in diabetic rats through the participation of RAGE and activation of NF-*κ*B.

TLR4/TLR2 may also play important roles in DN. Lin et al.[@bib48] first studied the effect of TLR4 on DN in human renal biopsies, human PTECs and an animal model and found that tubulointerstitial inflammation is promoted through the TLR4-mediated pathway. Furthermore, TLR2 contributes to inflammation in DN through NF-*κ*B activation[@bib49]. Recently, Mudaliar et al.[@bib50] showed that high glucose levels upregulate HMGB1 in cell supernatants and TLR4/TLR2 expression in human microvascular endothelial cells (HMEC-1). In addition, rHMGB1 was found to induce NF-*κ*B activation and synthesis of proinflammatory cytokines and chemokines, which were attenuated by inhibition of TLR2 or TLR4 signaling. Therefore it appears likely that hyperglycemia increases HMGB1 release and that it then binds to RAGE and TLR2/TLR4 to transduce inflammation through NF-*κ*B activation and contribute to DN.

4.4. HMGB1 and AAV {#s0040}
------------------

AAV is characterized by pauci-immune necrotizing inflammation of the small blood vessels. In a study of 30 AAV patients[@bib19], HMGB1 was found to be significantly higher in AAV with renal involvement and to remain higher in inactive cases than in historic healthy controls. Similarly, a study[@bib20] comparing plasma levels of HMGB1 in patients with active AAV with those in remission and normal controls found levels were higher in active AAV patients suggesting HMGB1 may be a marker of disease activity and a predictor of outcome in AAV.

4.5. HMGB1 and ccRCC {#s0045}
--------------------

ccRCC is the most common form of cancer of the kidney. In a study of 39 patients with pathologically confirmed ccRCC by Takeuchi et al.[@bib22], the immunohistological expression of HMGB1 in the cytoplasm was found to correlate with PT1b classification and tumor grade as previously found by Wu et al.[@bib51]. Takeuchi et al. also found evidence that the methylation of HMGB1 at lysine 112 in ccRCC affected its ability to bind to DNA and mediate its translocation. In a study[@bib52] examining the expression of HMGB1, RAGE and ERK1/2 phosphorylation in patients with ccRCC, HMGB1 released to cytoplasm was found to promote the development and progression of the disease *via* ERK1/2 activation, a process partially mediated by RAGE.

4.6. HMGB1 and nephritis {#s0050}
------------------------

### 4.6.1. HMGB1 and GN {#s0055}

Granulomas are distinctive chronic inflammatory lesions characterized by aggregations of activated macrophages and marked fibrosis. Infections, particulates and unidentified factors are thought to initiate their formation. However, the pathogenetic mechanisms remain obscure. Oyama et al.[@bib31] examined the expression of HMGB1 and MCP-1 in rats with crystal-induced GN and found the HMGB1 concentration was higher in renal granulomas, urine and serum, and that injection of HMGB1 worsened renal function and upregulated MCP-1. They concluded that HMGB1 was involved in GN and could be a novel target for inhibiting chronic granulomatous disease.

### 4.6.2. HMGB1 and LN {#s0060}

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease characterized by multiple organ involvement, production of autoantibodies to nuclear components, and immune complex deposition[@bib53]. LN is common in SLE and evidence suggests HMGB1 may play an important role. Thus a comparison of HMGB1 levels in 70 SLE patients and 35 healthy controls showed that serum levels in SLE patients were higher particularly in those with active renal disease[@bib54]. Furthermore, a study of 35 patients with active LN[@bib55] evaluated renal biopsies and serum levels of HMGB1 and found that renal tissue expression and serum levels were elevated in LN. Abdulahad et al.[@bib56] repeated this finding confirming that HMGB1 is associated with LN but providing no clarification as to its actual role. However, a recent study by Li et al.[@bib27] revealed macrophage activation induced by activated lymphocyte-derived DNA (ALD-DNA) contributes to the pathogenesis of murine LN and that only extracellular but not intracellular HMGB1 can significantly facilitate this activation and lead to LN. This suggests that reducing the release of HMGB1 from intracellular stores could ameliorate inflammation in LN.

5. Conclusions {#s0065}
==============

HMGB1 induces inflammation by binding to receptors on cell membranes (especially TLR2/4 and RAGE) and plays an important pathological role in many kidney diseases ([Table 2](#t0010){ref-type="table"}). Although the mechanisms by which HMGB1 is released and the signaling pathways it activates require further elucidation, evidence suggests that modulating HMGB1-mediated signaling may constitute a new strategy for the treatment of kidney diseases. Further animal and cell studies are required to evaluate how extracellular and intracellular HMGB1 are implicated in the pathogenesis of different kidney diseases.
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![Interaction of extracellular HMGB1 released from inflammatory and necrotic cells with cell surface receptors. (a) HMGB1 binds to RAGE which induces nuclear transcription of NF-*κ*B, leading to transcription and expression of target genes of cytokines and chemokines; (b) HMGB1 causes inflammation by interacting with TLR2/TLR4 through MyD88 dependent and independent pathways; (c) the heterocomplex formed by binding of HMGB1 and CXCL12 promotes the migration of monocytes and fibroblasts.](gr1){#f0005}

###### 

Sites of expression of HMGB1 in various renal diseases.

Table 1

  Renal disease                     Expression of HMGB1                                             Reference
  --------------------------------- --------------------------------------------------------------- ----------------------------------------
  Acute kidney injury               Serum                                                           [@bib23]
  Chronic kidney disease            Serum; urine;                                                   [@bib24], [@bib25], [@bib26]
  Renal fibrosis                    Renal proximal tubule epithelial cells (PTECs); M1 macrophage   [@bib32], [@bib33]
  Diabetic nephropathy              Renal glomerular cells; tubular epithelial cells                [@bib34]
  Renal involvement of ANCA-AAV     Serum; renal tissue                                             [@bib19], [@bib20]
  Clear cell renal cell carcinoma   Cytosol                                                         [@bib22]
  Granulomatous nephritis           Renal tissue                                                    [@bib31]
  Lupus nephritis                   Macrophages; renal tissue; serum; urine                         [@bib27], [@bib28], [@bib29], [@bib30]

###### 

Roles of HMGB1 in the pathogenesis of renal diseases.

Table 2

  Renal disease                     Receptor         Role of HMGB1                                                                                            Protection
  --------------------------------- ---------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Acute kidney disease              TLR4             Increase systemic circulating cyto/chemokines; mobilize bone marrow CD34-Flk1-cells to the circulation   Preconditioning with rHMGB1; MMF; CO-releasing molecule-2; glycyrrhizic acid
  Chronic kidney injury             RAGE             Enhance asymmetric dimethylarginine (ADMA)                                                               Inhibition of HMGB1-RAGE-ADMA axis
  Renal fibrosis                    RAGE TLR2        Induce transforming growth factor-*β*1 secretion from PTECs; facilitate M1 polarization                  Inhibit HMGB1 release
  Diabetic nephropathy              RAGE TLR2/TLR4   Activate NF-*κ*B                                                                                         Inhibit HMGB1 release
  Clear cell renal cell carcinoma   RAGE             Promote the development and progression of ccRCC *via* ERK1/2 activation                                 --
  Lupus nephritis                   --               Facilitate the ALD-DNA induced macrophage activation                                                     --

*Note:* "--" indicates no literature.
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